Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
New antimicrobial agents and novel combination therapies are needed to treat serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to daptomycin and vancomycin. The purpose of this study was to evaluate the combination of ceftaroline plus daptomycin or vancomycin in an in vitro pharmacokinetic/pharmacodynamic model. Simulations of ceftaroline-fosamil at 600 mg per kg of body weight every 8 h (q8h) (maximum free-drug concentration in serum [ fC max ], 15.2 mg/liter; half-life [ t 1/2 ], 2.3 h), daptomycin at 10 mg/kg/day ( f C max , 11.3 mg/liter; t 1/2 , 8 h), vancomycin at 2 g q12h ( fC max , 30 mg/liter; t 1/2 , 6 h), ceftaroline plus daptomycin, and ceftaroline plus vancomycin were evaluated against a clinical, isogenic MRSA strain pair: D592 (daptomycin susceptible and heterogeneous vancomycin intermediate) and D712 (daptomycin nonsusceptible and vancomycin intermediate) in a one-compartment in vitro pharmacokinetic/pharmacodynamic model over 96 h. Therapeutic enhancement of combinations was defined as ≥2 log 10 CFU/ml reduction over the most active single agent. The effect of ceftaroline on the membrane charge, cell wall thickness, susceptibility to killing by the human cathelicidin LL37, and daptomycin binding were evaluated. Therapeutic enhancement was observed with daptomycin plus ceftaroline in both strains and vancomycin plus ceftaroline against D592. Ceftaroline exposure enhanced daptomycin-induced depolarization (81.7% versus 72.3%; P = 0.03) and killing by cathelicidin LL37 ( P < 0.01) and reduced cell wall thickness ( P < 0.001). Fluorescence-labeled daptomycin was bound over 7-fold more in ceftaroline-exposed cells. Whole-genome sequencing and mutation analysis of these strains indicated that change in daptomycin susceptibility is related to an fmtC ( mprF ) mutation. The combination of daptomycin plus ceftaroline appears to be potent, with rapid and sustained bactericidal activity against both daptomycin-susceptible and -nonsusceptible strains of MRSA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationWhole genome sequencing of meticillin-resistant Staphylococcus aureus
Kuroda, M., Ohta, T., Uchiyama, I., Baba, T., Yuzawa, H., Kobayashi, I., Cui, L., Oguchi, A., Aoki, K.-I., Nagai, Y., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04403-2 · Cited by 1,961
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir034 · Cited by 1,599
Self-citationStampy: A statistical algorithm for sensitive and fast mapping of Illumina sequence reads
Lunter, G., & Goodson, M. (2011) · Genome Research · doi:10.1101/gr.111120.110 · Cited by 1,016
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Peschel, A., Jack, R. W., Otto, M., Collins, L. V., Staubitz, P., Nicholson, G., Kalbacher, H., Nieuwenhuizen, W. F., Jung, G., Tarkowski, A., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.9.1067 · Cited by 786
Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656
De novo bacterial genome sequencing: Millions of very short reads assembled on a desktop computer
Hernandez, D., François, P., Farinelli, L., Østerås, M., & Schrenzel, J. (2008) · Genome Research · doi:10.1101/gr.072033.107 · Cited by 629
Mwangi, M. M., Wu, S. W., Zhou, Y., Sieradzki, K., de Lencastre, H., Richardson, P., Bruce, D., Rubin, E., Myers, E., Siggia, E. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609839104 · Cited by 538
Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureus
Cui, L., Ma, X., Sato, K., Okuma, K., Tenover, F. C., Mamizuka, E. M., Gemmell, C. G., Kim, M.-N., Ploy, M.-C., El Solh, N., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.1.5-14.2003 · Cited by 492
Wootton, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.399 · Cited by 414 · cited 1×
“Glycopeptide heteroresistance in D592 was confirmed by previously described methods (30).”
BackgroundBenvenuto, M., Benziger, D. P., Yankelev, S., & Vigliani, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00247-06 · Cited by 319
Jones, T., Yeaman, M. R., Sakoulas, G., Yang, S.-J., Proctor, R. A., Sahl, H.-G., Schrenzel, J., Xiong, Y. Q., & Bayer, A. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00719-07 · Cited by 318
Self-citationDhand, A., Bayer, A. S., Pogliano, J., Yang, S.-J., Bolaris, M., Nizet, V., Wang, G., & Sakoulas, G. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir340 · Cited by 252 · cited 8×
“The parent strain (D592) is a DAP-susceptible (DS) hVISA strain that mutated into a DNS VISA strain (D712) over a 20-day period of antimicrobial therapy that included VAN and DAP (14).”
BackgroundResultInfluentialSelf-citationPogliano, J., Osborne, N., Sharp, M. D., Abanes‐De Mello, A., Perez, A., Sun, Y., & Pogliano, K. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01255.x · Cited by 246
Self-citationSakoulas, G., Bayer, A. S., Pogliano, J., Tsuji, B. T., Yang, S.-J., Mishra, N. N., Nizet, V., Yeaman, M. R., & Moise, P. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05551-11 · Cited by 176 · cited 3×
“Exposure to beta-lactams increases binding of DAP and cationic microbicidal peptides to cell membranes and enhances the bactericidal activity of these compounds in both MRSA and enterococci (14, 15).”
BackgroundResultSelf-citationPerspectives on Daptomycin Resistance, with Emphasis on Resistance in Staphylococcus aureus
Boucher, H. W., & Sakoulas, G. (2007) · Clinical Infectious Diseases · doi:10.1086/520655 · Cited by 174
Self-citationBlaser, J. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/15.suppl_a.125 · Cited by 156
Sieradzki, K., Leski, T., Dick, J., Borio, L., & Tomasz, A. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.4.1687-1693.2003 · Cited by 135
Yang, S.-J., Xiong, Y. Q., Boyle-Vavra, S., Daum, R., Jones, T., & Bayer, A. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00487-10 · Cited by 130
Sieradzki, K., & Tomasz, A. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.24.7566-7570.1999 · Cited by 125
Villegas‐Estrada, A., Lee, M., Hesek, D., Vakulenko, S. B., & Mobashery, S. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8029448 · Cited by 118
Xiong, Y. Q., Mukhopadhyay, K., Yeaman, M. R., Adler-Moore, J., & Bayer, A. S. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3114-3121.2005 · Cited by 118
Yang, S.-J., Nast, C. C., Mishra, N. N., Yeaman, M. R., Fey, P. D., & Bayer, A. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00122-10 · Cited by 114
Rose, W. E., Schulz, L. T., Andes, D., Striker, R., Berti, A. D., Hutson, P. R., & Shukla, S. K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00797-12 · Cited by 111
Self-citationKraus, D., Herbert, S., Kristian, S. A., Khosravi, A., Nizet, V., Götz, F., & Peschel, A. (2008) · BMC Microbiology · doi:10.1186/1471-2180-8-85 · Cited by 100
Yin, S., Daum, R. S., & Boyle-Vavra, S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.336-343.2006 · Cited by 88
Finan, J. E., Archer, G. L., Pucci, M. J., & Climo, M. W. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3070-3075.2001 · Cited by 77
Berti, A. D., Wergin, J. E., Girdaukas, G. G., Hetzel, S., Sakoulas, G., & Rose, W. E. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00502-12 · Cited by 73
Self-citationVidaillac, C., Leonard, S. N., & Rybak, M. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00636-09 · Cited by 70
Self-citationHagihara, M., Wiskirchen, D. E., Kuti, J. L., & Nicolau, D. P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05473-11 · Cited by 64
Steed, M. E., Vidaillac, C., & Rybak, M. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00536-10 · Cited by 57
Self-citationLeonard, S. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042103 · Cited by 53
Steed, M. E., Werth, B. J., Ireland, C. E., & Rybak, M. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01185-12 · Cited by 37
Self-citationLeonard, S. N., & Rybak, M. J. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn439 · Cited by 35
Self-citationSteed, M. E., Vidaillac, C., & Rybak, M. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00347-11 · Cited by 34
Self-citationRiccobene, T. A. (2008) · 46th Annual Meeting · Cited by 22
Research works printed but not linked: 1
- SakoulasG RoseWE. 2011. Effect of beta-lactam (BL) exposure in vitro on daptomycin (DAP) activity and cell wall thickness in MRSA, poster E-1332. Abstr. 51st Annu. Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citationThe Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent
Ridyard, K. E., & Overhage, J. (2021) · Antibiotics · doi:10.3390/antibiotics10060650 · Cited by 270
“DAP exhibits antibacterial effects against heterogeneous VAN-intermediate S. aureus (hVISA), VISA [208], MRSA and vancomycin-resistant enterococci (VRE) [207].”
BackgroundInfluentialA Current Perspective on Daptomycin for the Clinical Microbiologist
Humphries, R. M., Pollett, S., & Sakoulas, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-13 · Cited by 240
Self-citationWhole-Genome Analyses of Enterococcus faecium Isolates with Diverse Daptomycin MICs
Diaz, L., Tran, T. T., Munita, J. M., Miller, W. R., Rincon, S., Carvajal, L. P., Wollam, A., Reyes, J., Panesso, D., Rojas, N. L., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02686-14 · Cited by 139
Metadata
- Authors
- Werth, B. J., Sakoulas, G., Rose, W. E., Pogliano, J., Tewhey, R., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- New York Medical College (US)
- University of Wisconsin–Madison (US)
- University of California San Diego (US)
- Scripps Research Institute (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-01
- Volume
- 57
- Issue
- 1
- Pages
- 66-73
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3535972
- OpenAlex
- W2138194474
- Semantic Scholar
- 39f34553cf23e3b9cdab27a62a417c2840f7a855
- Cited by
- 134
- References
- 40
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 11 · 2020: 13 · 2019: 8 · 2018: 8 · 2017: 7 · 2016: 11 · 2015: 12 · 2014: 19 · 2013: 12
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Update notices
- correction (2013-02-14)
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (R21A1092055-01)
- National Center for Research Resources (UL1RR025774)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- ceftaroline, daptomycin, vancomycin-intermediate Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, combination antibiotic therapy, pharmacokinetic-pharmacodynamic modeling, membrane depolarization, cell wall thickness, ceftaroline fosamil
- MeSH terms
- Ceftaroline, Anti-Bacterial Agents, Bacterial Proteins, Cell Membrane, Cell Wall, Cephalosporins, Drug Combinations, Drug Synergism, Fluorescent Dyes, Models, Biological, Mutation, Vancomycin, Colony Count, Microbial, Genome, Bacterial, Daptomycin, Aminoacyltransferases, Vancomycin Resistance, Antimicrobial Cationic Peptides, Microbial Viability, Cathelicidins, Methicillin-Resistant Staphylococcus aureus, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.